Attention Deficit Hyperactivity Disorder (ADHD) and cervical cancer are now covered under the National Health Fund’s (NHF) ...
The National Health Fund (NHF) has announced that effective March 27, 2025, attention deficit hyperactivity disorder (ADHD) and cervical cancer are covered on the NHF's Card Programme, bringing the ...
Zacks Investment Research on MSN4d
5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar PortfolioWall Street is suffering from volatility in the first quarter of 2025. Out of the three large-cap indexes, the S&P 500 and ...
Gastroparesis is a chronic gastrointestinal condition that happens when the stomach can’t empty well, causing delayed ...
Operator: Good afternoon, and welcome to the Evoke Pharma, Inc. Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently, all callers have been placed in a listen-only mode.
The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback